| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Emtricitabine/tenofovir disoproxil |
| Brand | TEVA® |
| Indication | For pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk |
| Assessment Process | |
| Rapid review commissioned | 11/12/2017 |
| Rapid review completed | 21/12/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |